REFERENCES
- Ogawa S, Takita J, Sanada M, Hayashi Y. Oncogenic mutations of ALK in neuroblastoma. Cancer Sci. 2011;102:302–308.
- Tajiri T, Souzaki R, Kinoshita Y, Concordance for neuroblastoma in monozygotic twins: case report and review of the literature. J Pediatr Surg. 2010;45:2312–2316.
- Mosse YP, Laudenslager M, Longo L, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935.
- Bourdeaut F, Ferrand S, Brugieres L, ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur J Hum Gent. 2012;20:291–297.
- Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–16703.
- US National Library of Medicine. ClinicalTrials.gov [online], http: //clinicaltrials.gov/ct2/show/NCT 00939770 (2012).
- Carpenter EL, Mosse YP. Targeting ALK in neuroblastoma- preclinical and clinical advancements. Nat Rev Clin Oncol. 2012;7;391–399.
- Carpenter El, Haglund EA, Mace EM, Antibody targeting of anaplastic lymphoma kinase induced cytotoxicity of human neuroblastoma. Oncogene. 2012; doi: 10.1038 /onc.2011.647.
- Schonherr C, Ruuth K, Kamaraj S, Anaplastic Lymphoma Kinase(ALK) regulates initiation of transcription of MYC in neuroblastoma cell. Oncogene. 2012. doi: 10.1038 /onc.2012.12.
- Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene. 2010;29:1566–1579.